MedTrace Logo

Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura

NCT06137105 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-11-18

No results posted yet for this study

Summary

1. Assesement of response to Thrombopoietin receptor agonists (TPO-RAs) as treatment in Idiopathic thrombocytopenia purpura patients in Assiut University hospital.
2. Explore side effects of Thrombopoietin receptor agonists in Idiopathic thrombocytopenia purpura .
3. To study effect of thrombopoietin receptor agonists and Quality life in Idiopathic thrombocytopenia purpura patients.

Conditions

  • ITP - Immune Thrombocytopenia

Interventions

DRUG

eltrombopag and romiplastim

Group I: eltrombopag and romiplastim Group II : recived corticosteroid.

Sponsors & Collaborators

  • Association for Training, Education, and Research in Hematology, Immunology, and Transplantation

    collaborator OTHER

  • Assiut University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2026-12-31
Completion
2026-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06137105 on ClinicalTrials.gov